Mounjaro® (tirzepatide) Product Theater by Lilly USA, Inc.

Join a presentation from one of your peers to learn about Mounjaro, a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve glycemic control in adults with type 2 diabetes (T2D). This presentation will include a review of clinical efficacy and safety results, and how to get your adult patients with T2D started on Mounjaro. Attendees will have the opportunity to pose questions to the speaker at the end of the session.

Please see the Important Safety Information for Mounjaro, including Boxed Warning about possible thyroid tumors, including thyroid cancer, the Full Prescribing Information, and Medication Guide provided at the product theater.

This program is sponsored by, and the speaker is presenting on behalf of, Lilly USA, LLC. It is being presented consistent with FDA guidelines and is not approved for continuing education credit.